d-Lenolate® Studies and
Several significant studies have been made and
published documenting the powerful correlation of both Olive Leaf Extract and
specifically d-Lenolate to a myriad of life threatening viral and bacterial
diseases. The following are studies and research of highly defining
studies that document in two distinct methodologies the effectiveness and
efficacy of d-Lenolate®.
Studies & Research:
Vitro HSV-1 Testing
& Extra Cellular Bacterial Infection
Infections (E.coli, Pseudomonas Aeruginosa, Yeast)
Activities of d-Lenolate®
Crohns Disease, Candida
The purpose of this study was
to test the immune effects of d-Lenolate® in healthy volunteers at the
Department of Cytogenetics and Immunology of NICS. This study examines the
effect of 21 days of d-Lenolate® treatment on the immune parameters of healthy
The effect of d-Lenolate® on the Immune Parameters in
Findings: d-Lenolate® showed a potential immune building response along
with the ability to fight off weak, solid, and strong bacterial stimuli.
Herpes Simplex I
East Park Research, in
a coordinated effort with one of the foremost research Universities in the
world, has been testing its Topical for the past two years on various skin
conditions to determine its efficacy in a scientific clinical environment.
d-Lenolate®, Aloe, and Neem Tissue Culture Experiments
Findings: It was shown at the conclusion of this first phase of testing
that Oleuropein has a direct improving effect on cold sores, also known as Type
I Herpes. It was shown to assist in the healing of human tissue where Herpes
symptoms are present.
The findings, using
tissue cultures and Herpes Simplex Type I, were so positive in fact that East
Park Research was encouraged to develop a safe and effective cream product for
cold sores associated with Herpes Simplex I (HSV1), DELEVE. One of the
most important findings was the proper concentration of each ingredient to make
the most effective anti-viral solution. The inhibition of spreading is one of the
very exciting properties of this final formulation.
The cold sore
formulation containing d-Lenolate® was evaluated for its safety in animals.
There were no toxic effects observed.
LSU Safety Report
Findings: The treated skin remained clear of
inflammation and redness and all animals appeared normal throughout the
duration of the study.
In Vitro HSV-1 Testing
evaluated as an antiviral for effectiveness in treating herpes infections.
In Vitro Anti-HSV-1 Activities of d-Lenolate®
at Different Concentrations
Findings: Treatment of mice infected with virulent human strain of herpes
simplex virus type-I (HSV-1) with formulation containing a higher concentration
of d-Lenolate® and other compounds resulted in highly significant protection of
mice against all disease outcomes including substantial decrease in animals
with herpes symptoms.
Dr. Sergui Popov of
George Mason University, a globally acknowledged expert on the study of anthrax
performed a study in 2006. His protocol focuses a direct application of
d-Lenolate®, to test its ‘antibiotic” properties directly on the spores.
Study: Anti-B Anthracis Activities of Olive Leaf Extract: In Vitro
Influenza & Extra Cellular Bacterial
Two “animal” studies,
performed by a very prominent Japanese research organization, focuses on the
effects of d-Lenolate® on the body’s immune system and how the enhanced immune
system then eradicates some of the world’s most deadly viruses and bacteria.
Enhanced Resistance against Influenza Virus by Treatment
with Dietary supplement d-Lenolate® in Neutropenic Mice Induced
Findings: d-Lenolate® appears to be a successful
treatment for influenza and extra cellular bacterial infection. It is
particularly useful as preventative treatment prior to exposure and as a
treatment to enhance healing in exposed and immunocompromised mice.
Microbial Infections (E.coli, Pseudomonas
evaluated as a protective agent against two bacterial species in
mice: E.coli and Pseudomonas aeruginosa; and the yeast, Candida albicans.
Study: Therapeutic Effect of
d-Lenolate® Against Experimental Infections in Immuno-compromised Mice
Findings: d-Lenolate® enhanced the restoration of
white blood cells to the normal level and protected against
infection with bacteria and yeast. In this study, d-Lenolate® restored PMN
levels in immunocompromised mice and also enhanced clearance of E.coli from
blood, both restorative effects after infection with bacteria. These two
factors make d-Lenolate® a powerful protectant from infection as well as an
enhancer to recovery post infection. d-Lenolate® was able to restore
immune function after treatment with all of these agents.
In this study
conducted by the Japanese scientists, d-Lenolate® was able to restore antibody
production after chemotherapy. Therefore, d-Lenolate® functions in the early
stages of infection by enhancing PMN number and function antibody production
capability of B cells. All of these d-Lenolate®-induced functions make the
efficacy of cellular mechanisms in late stage influenza virus infection more
successful when the immune system is depressed and at least equivalent to
healthy mice responses.
Antimicrobial Activities of d-Lenolate®
to antimicrobials increases the fatality rate of infections, and the prolonged
disease state allows greater chance for pathogenic organism to spread across
Study: Antimicrobial Activity of d-Lenolate®
Findings: Recent research at University of Nevada Las Vegas (UNLV) has
revealed that d-Lenolate® demonstrates effective direct anti-microbial activity
against representatives of both Gram positive and Gram negative bacterial.
Expanded research also showed that d-Lenolate® is effective in inhibiting
growth of several hospital-based pathogens.
In January of 1999,
Dr. Bernard J. Mizock evaluated the efficacy of d-Lenolate®, to determine its
effectiveness in reducing the burden of Candida Albicans, a single cell fungi
living in the blood that confuses inter-cell communication and is the
underlining cause of many ill-health problems according to the CDC.
Evaluation of the Efficacy of d-Lenolate® in the Control of
Symptoms of Candida Hypersensitivity Syndrome
Findings: Nystatin is the drug of choice and in a 32
week study did 2% better than placebo while d-Lenolate® reduced the symptoms by
greater than 50% in 60 days with no apparent side effects. East Park believes
that with the appropriated testing, d-Lenolate® will be proven to be a powerful
treatment for many common ailments.
d-Lenolate® was used
by Dr. Mizock in a second study to record the modifications of symptoms related
to arthritic symptoms. Using the Western Ontario and McMaster
Universities Arthritis (WOMAC) index, scores were obtained during the period of
September 2000 to January 2001 at baseline, 20, 40 and 60 days.
of d-Lenolate® in Modifying Symptoms of Arthritis
Findings: Dr. Mizock concluded that East Park’s
d-Lenolate® improves the symptoms of arthritis. The effects were first
noted at 20 days, and reach a maximum effect of 32% improvement at 40 days.
Psoriasis, Crohn’s Disease, Candida
In 2002, the Chief of
Medicine at Budapest General Hospital noted that his experience with fighting
infection by prescribing d-Lenolate® had reach a success rate of 90 percent and
had been using d-Lenolate® before resorting to any antibiotics.
Two in-vitro tests
were performed in 2007 by a group of prominent biochemists associated with some
of the most prominent research institutions in the world, including NYU School
of medicine, Massachusetts General Hospital, and Harvard Medical School. These
tests focused on the use of Oleuropein as an inhibitor of the HIV virus. One of
these tests was executed under a grant by the National Institute of Health.
Findings: Both of studies concluded that Oleuropein is
an effective inhibitor of the HIV virus and that under certain conditions a
“complete inhibition” occurred.
West Nile Virus
Upon the West Nile
Virus epidemic in the United States, a study was conducted to determine
the in-vitro anti-West Nile Virus (WNV) activities of d-Lenolate at different
of d-Lenolate® in combating the West Nile Virus
Findings: The d-Lenolate filtrate demonstrated
anti-WNV activity at higher concentrations. The effect decreased with